Remus Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Remus Pharmaceuticals has been growing earnings at an average annual rate of 69.3%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 80% per year. Remus Pharmaceuticals's return on equity is 24.9%, and it has net margins of 10.1%.
Key information
69.3%
Earnings growth rate
62.7%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 80.0% |
| Return on equity | 24.9% |
| Net Margin | 10.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21Revenue & Expenses Breakdown
How Remus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,129 | 215 | 74 | 0 |
| 31 Mar 23 | 451 | 85 | 55 | 0 |
| 31 Mar 22 | 247 | 34 | 34 | 0 |
| 31 Mar 21 | 188 | 10 | 30 | 0 |
| 31 Mar 20 | 124 | 8 | 31 | 0 |
Quality Earnings: REMUS has a high level of non-cash earnings.
Growing Profit Margin: REMUS's current net profit margins (10.1%) are lower than last year (18.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REMUS's earnings have grown significantly by 69.3% per year over the past 5 years.
Accelerating Growth: REMUS's earnings growth over the past year (153.3%) exceeds its 5-year average (69.3% per year).
Earnings vs Industry: REMUS earnings growth over the past year (153.3%) exceeded the Healthcare industry 30.6%.
Return on Equity
High ROE: REMUS's Return on Equity (24.9%) is considered high.